The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook on Vicarious Surgical's stock. The price target of $0.6 indicates the analyst's expectation of the stock's potential market price, which may influence investor sentiment and could lead to increased trading activity. However, since the rating is neutral, the immediate impact on the stock price may be limited unless the market was expecting a more positive or negative outlook.